NCT06481592招募中2 期
A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Endometrial Cancer.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 12
- 主要终点
- Objective Response Rate
研究概览
简要总结
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
详细描述
The study will enroll participants with advanced endometrial cancer who previously received treatment with platinum-based chemotherapy and an anti-programmed cell death protein-1 (PD-1)/programmed death ligand 1 (PD-L1) agent in a recurrent or advanced setting, either sequentially or in combination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Participants must have a histologically confirmed diagnosis of endometrial carcinoma. All histologies, including carcinosarcoma, will be allowed. Uterine sarcoma will not be allowed.
- •Participants who have received the following previous therapies:
- •At least 1 but no more than 4 lines of prior systemic therapy with no more than 2 lines of chemotherapy in any setting (ie, neoadjuvant or adjuvant setting as well as for recurrent, metastatic, or primary unresectable disease. .
- •Participants have received platinum-based chemotherapy and anti-PD-1/PD-L1 therapy.
- •Participants who declined platinum-based chemotherapy regimen and/or an anti-PD-1/PD-L1 therapy or were deemed ineligible for such therapies by the investigator may be considered after discussion with the medical monitor.
- •Systemic therapy counting towards lines of therapy includes chemotherapy, targeted therapy, immunotherapy, and antibody drug conjugates, given alone or in combination. Hormonal therapy does not count as a line of therapy.
- •Participants must have either (i) documented radiographic disease progression during or after the last line of therapy or (ii) discontinued their last line of therapy because of treatment intolerance or toxicity or (iii) with medical monitor discussion, participant/physician decision in the context of stable disease with evidence of tumor growth.
- •Participants who have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and estimated life expectancy of >6 months.
- •Participants having at least one resectable lesion and at least one measurable lesion, following resection of the lesion for TIL generation.
- •Participants who have adequate organ function, including adequate cardiopulmonary function.
- •Participants of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and up to 12 months after the last dose of study intervention.
- •Participants who are >70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.
排除标准
- •Participants who have symptomatic untreated brain metastases.
- •Participants who have had a history of allogeneic organ transplant or any form of cell therapy involving prior conditioning chemotherapy within the past 20 years.
- •Participants who require systemic steroid therapy > 10 mg/day prednisone or another steroid equivalent dose.
- •Participants who have any form of primary immunodeficiency.
- •Participants who have another primary malignancy within the previous 3 years.
- •Participants who have received or will receive a live or attenuated vaccination within 28 days prior to the start of the NMALD.
研究组 & 干预措施
Patients with Endometrial Cancer
Experimental
干预措施: Lifileucel (Biological)
结局指标
主要结局
Objective Response Rate
时间窗: Up to 5 Years
To evaluate the proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1.
次要结局
- Complete Response Rate(Up to 5 Years)
- Overall Survival(Up to 5 Years)
- Duration of Response(Up to 5 Years)
- Disease Control Rate(Up to 5 Years)
- Progression-Free Survival(Up to 5 Years)
- Adverse Events(Up to 5 Years)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
2 期
Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:Locally Advanced Pancreatic Carcinoma(LAPC)NCT03861702Nelson Yee28
已完成
2 期
A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)Multidrug Resistant TuberculosisNCT01859923Otsuka Pharmaceutical Development & Commercialization, Inc.37
招募中
1 期
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine CarcinomaNCT06157827Nanjing Leads Biolabs Co.,Ltd178
已完成
2 期
A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast CancerHER-2 Positive Breast CancerNCT02488564Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori49
已完成
1 期
Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)Carcinoma, HepatocellularLiver NeoplasmsNCT00122876Light Sciences Oncology25